3653 results for «358»
3653 results
Radial and distal radial artery access for PCI
19 May 2026 – From EuroPCR 2026
This session provides an in-depth evaluation of radial and distal radial artery access for PCI, including a 20-year trend analysis of clinical outcomes, feasibility studies on distal radial interventions, and comparative real-world experiences. It also features meta-analyses of randomized trials on access approaches and early findings...
Devices and strategies in calcified lesions
21 May 2026 – From EuroPCR 2026
Explore advanced devices and techniques for treating calcified coronary lesions in this session. Discussions include the use of Eximer laser coronary atherectomy, novel cutting balloons, outcomes of rotational atherectomy in tortuous vessels, atherectomy combined with drug-coated balloon therapy, and calcium fracture patterns following Shockwave intravascular lithotripsy.
Treatment for calcified coronary artery disease in the real world
19 May 2026 – From EuroPCR 2026
This session presents real-world experiences and evidence on treating calcified coronary artery disease. It includes meta-analyses comparing rotational atherectomy and balloon angioplasty, long-term outcomes of excimer laser atherectomy, and multicenter registry data on intravascular lithotripsy (IVL), particularly in diabetic and high-risk patients. The session also focuses...
Addressing difficult anatomy in STEMI patients
21 May 2026 – From EuroPCR 2026
This session addresses the challenges of managing difficult coronary anatomy in STEMI patients through a series of complex case studies. Topics include management of aneurysms, rare aorto-ostial lesions, thrombosis interplay, PPCI in dextrocardia situs inversus, and hybrid PCI approaches for multifaceted coronary issues.
TAVI complications: impact and improvement
20 May 2026 – From EuroPCR 2026
This session examines critical complications associated with TAVI and strategies to mitigate their impact. Topics include carbon-dioxide flushing to reduce brain injury, management of cardiac tamponade, AI-driven customization of TAVI in complex anatomies, and the influence of vascular complications on post-procedural quality of life.
INOCA/ANOCA: technical aspects
20 May 2026 – From EuroPCR 2026
This session covers technical aspects critical to the evaluation and management of ischemia with non-obstructive coronary arteries (INOCA) and angina with non-obstructive coronary arteries (ANOCA). Key topics include the impact of guide catheter shape, injection techniques for thermodilution measurements, advanced perfusion CMR diagnostics, and the physiological...
FFR and non-hyperaemic pressure ratios
20 May 2026 – From EuroPCR 2026
This session presents contemporary clinical applications of fractional flow reserve (FFR) and non-hyperaemic pressure ratios (NHPR), highlighting real-world impacts of physiology microcatheter-based indices, the interplay between epicardial stenosis and microvascular resistance, post-PCI hyperemia effects on iFR, and machine-learning driven outcome predictions.
Other right-sided and tricuspid valve interventions
20 May 2026 – From EuroPCR 2026
This session focuses on right-sided heart valve interventions, particularly targeting tricuspid valve disease. Topics include clinical outcomes in atrial functional tricuspid regurgitation, management in the context of left-sided valvular disease, treatment approaches for tricuspid valve endocarditis, and advances in transcatheter therapies and device placements.
SURTAVI: five-year results from a randomized trial of TAVR vs. SAVR in patients at intermediate surgical risk
07 Nov 2021
Although TAVI is an accepted alternative to surgery in patients with severe aortic stenosis who are at high surgical risk, less is known about long-term comparative outcomes among patients with aortic stenosis who are at intermediate surgical risk. P. Redaelli & M. Pighi review the SURTAVI trial...
Author
Author
World Heart Day 2023: Reducing the burden of cardiovascular disease globally: beyond stents and balloons!
29 Sep 2023
Global burden of Cardiovascular Disease
Cardiovascular disease (CVD) remains the lead cause of mortality for men and women globally. Our world population in 2023 is 8 billion! Of these, around 620 million people are living with heart and circulatory diseases across the world. Each year around 60...
Author
BRIGHT-4 – Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial
07 Nov 2022
Nicola Ryan provides her take on the BRIGHT-4 study, which was presented during AHA 2022 in Chicago, & simultaneously published in the Lancet.
This study was a randomised control trial designed to assess if bivalirudin plus a high dose infusion for 2-4 hours post PPCI was superior to unfractionated...
Author
The Lancet Commission to reduce global burden of cardiovascular disease in women by 2030
29 Aug 2021
Vijay Kunadian summarizes the key points of the LBT session of the ESC congress 2021 held on Sunday, 29 August focusing on the Lancet Commission to reduce the global burden of heart disease in women by 2030.
Author
Drug-coated balloon (DCB) technology: A pioneer’s view of the historical evolution and future directions
08 Jan 2025
In this article, Bruno Scheller explores advances in local drug delivery, from drug-coated balloons to novel antiproliferative agents. These innovations aim to reduce restenosis, minimize permanent implants, and pave the way for patient-specific coronary artery disease treatments.
Author
